An observational study in Carcinoma, Hepatocellular and Carcinoma, Renal Cell, sponsored by Bayer. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 91 Years. Per ClinicalTrials.gov, last updated 2015-09-21.
Sponsored by Bayer · Observational
This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar
The objectives of this surveillance are to identify problems/questions regarding the followings in the clinical practice of using Nexavar®.
6,745 studies on the registry are indexed under Carcinoma; 1,163 are open to participants now.
This study's enrollment of 2,845 is above the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Bayer is the lead sponsor of 1,643 studies on the registry; 57 are open to participants now.
Of its 209 completed or terminated interventional studies of FDA-regulated products, 129 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with diagnosis of advanced renal cell carcinoma or hepatocellular carcinoma and decision taken by the physician to precribe Nexavar
Exclusion Criteria:
Drug: Sorafenib (Nexavar, BAY43-9006)
Daily dose, dosage frequency and duration will be decided by physicians.
Adverse events collection
Time frame: From start of treatment to 4 weeks after discontinuation of treatment
Duration of treatment, dosage and indication
Time frame: Whole treatment period
Tumor status
Time frame: Whole treatment period
Performance status
Time frame: Whole treatment period
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bayer